International Association for the Study of Lung Cancer

Recent papers from International Association for the Study of Lung Cancer

1. Evaluating immunocytochemistry performance in lung cancer cytology: An IASLC Cytology Working Group studyCancer Cytopathology · 2026
2. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trialThe Lancet · 2026
3. A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancerOncoImmunology · 2026
4. Program Guidelines for the National Lung Cancer Screening Program: Targeted Lung Cancer Screening in High‐Risk Individuals in AustraliaThe Medical Journal of Australia · 2026
5. A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with EGFR -mutant, MET -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).Journal of Clinical Oncology · 2026
6. Adjuvant erlotinib versus observation after complete resection of EGFR -mutant NSCLC: Final overall survival results of Alliance A081105.Journal of Clinical Oncology · 2026
7. Immune-related adverse event severity and clinical outcomes with immune checkpoint inhibitor immunotherapy in participants with non–small cell lung cancer: Analysis of the lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A.Journal of Clinical Oncology · 2026
8. A large prospective patient-advocacy assessment of fears, concerns, and challenges in patients diagnosed with lung cancer in the United States.Journal of Clinical Oncology · 2026
9. The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancerCancer · 2026
10. Abstract 6353: Age-related differences in lung cancer patients’ and caregivers' perceptions and challenges: 2025Cancer Research · 2026
11. Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesESMO Open · 2026
12. A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumorsCancer Chemotherapy and Pharmacology · 2025
13. Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and StrategiesJTO Clinical and Research Reports · 2025
14. Integrating AI literacy into library and information science education and practice: a human-centered approachLibrary Hi Tech News · 2025
15. Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP StudyClinical Cancer Research · 2025
16. Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery DataJTO Clinical and Research Reports · 2025
17. State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care ProgramsJTO Clinical and Research Reports · 2024
18. S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic CarcinomaJTO Clinical and Research Reports · 2024
19. Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): Survival differences in the context of race, gender and smoking.Journal of Clinical Oncology · 2024
20. Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial2024